公开(公告)号：US20240358705A1

公开(公告)日：2024-10-31

申请号：US18649074

申请日：2024-04-29

Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

Inventor： Phaethon Philbrook ,  Augusto Ochoa ,  Matthew Dean

IPC: A61K31/519 ,  A61K31/136 ,  A61K31/192 ,  A61K31/198 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0783

CPC classification number: A61K31/519 ,  A61K31/136 ,  A61K31/192 ,  A61K31/198 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/4632 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0636 ,  C12N2501/51 ,  C12N2501/515

Abstract: The invention provides a method of preventing, treating, and/or preventing the recurrence of cancer in a subject by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Further, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of cancer. Still further, the invention provides a method of preventing or treating an inflammatory response in a subject. Also provided is a method of preventing an immune system disease or disorder in a subject. Further, the invention provides a method treating an immune system disease or disorder in a subject. Also, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of an immune system disease or disorder.

公开(公告)号：US12128045B2

公开(公告)日：2024-10-29

申请号：US17306052

申请日：2021-05-03

Applicant: BTG International Limited

Inventor： Udai Banerji

IPC: A61K31/517 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/502 ,  A61K31/519 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/00 ,  A61K39/395 ,  A61K47/64 ,  A61K47/69 ,  A61P35/00

CPC classification number: A61K31/517 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/502 ,  A61K31/519 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/3955 ,  A61K47/643 ,  A61K47/6929 ,  A61P35/00 ,  A61K2039/545

Abstract: A compound of formula I or a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration. Method of treatment and novel dosage forms are also provided. Particularly treated are ovarian cancers, particularly those expressing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.

公开(公告)号：US20240350449A1

公开(公告)日：2024-10-24

申请号：US18763671

申请日：2024-07-03

Applicant: ABILITY PHARMACEUTICALS S.L.

Inventor： Carles DOMÈNECH GARCIA ,  José Alberto ALFÓN CORIAT ,  Héctor PÉREZ MONTOYO ,  Miguel Francisco SEGURA GINARD ,  Jose Miguel LIZCANO DE VEGA

IPC: A61K31/282 ,  A61K31/201 ,  A61K31/337 ,  A61K33/243 ,  A61K45/06 ,  A61P35/04

CPC classification number: A61K31/282 ,  A61K31/201 ,  A61K31/337 ,  A61K33/243 ,  A61K45/06 ,  A61P35/04

Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.

公开(公告)号：US12115226B2

公开(公告)日：2024-10-15

申请号：US17271882

申请日：2019-08-28

Applicant: Academy of Military Medical Sciences

Inventor： Xinbo Zhou ,  Yanming Wang ,  Song Li ,  Wu Zhong ,  Shiyong Fan ,  Dian Xiao ,  Junhai Xiao ,  Zhibing Zheng ,  Xingzhou Li ,  Yunde Xie ,  Ruiyuan Cao ,  Xiaokui Wang

IPC: A61K47/68 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/5517 ,  A61K31/704 ,  A61K38/07 ,  A61K47/54 ,  A61P35/00 ,  C07C237/04 ,  C07D207/452 ,  C07D233/94 ,  C07D307/71 ,  C07D333/44 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12

CPC classification number: A61K47/6811 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/537 ,  A61K31/5517 ,  A61K31/704 ,  A61K38/07 ,  A61K47/545 ,  A61K47/6803 ,  A61K47/6809 ,  A61P35/00 ,  C07C237/04 ,  C07D207/452 ,  C07D233/94 ,  C07D307/71 ,  C07D333/44 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12

Abstract: The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease

公开(公告)号：US12115171B2

公开(公告)日：2024-10-15

申请号：US17836836

申请日：2022-06-09

Applicant: Massachusetts Institute of Technology

Inventor： Michael B. Yaffe ,  Jesse C. Patterson

IPC: A61K31/58 ,  A61K31/337 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/567 ,  A61K31/573 ,  A61K31/575 ,  A61K45/06

CPC classification number: A61K31/58 ,  A61K31/337 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/567 ,  A61K31/573 ,  A61K31/575 ,  A61K45/06 ,  A61K31/567 ,  A61K2300/00 ,  A61K31/575 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/58 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/4409 ,  A61K2300/00

Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.

公开(公告)号：US20240327509A1

公开(公告)日：2024-10-03

申请号：US18575044

申请日：2022-11-22

Applicant: CELLUS,INC.

Inventor： Sun Wook CHO ,  Seong Keun KIM

IPC: C07K16/24 ,  A61K31/337 ,  A61K39/395 ,  A61K47/68 ,  G01N33/574

CPC classification number: C07K16/24 ,  A61K31/337 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6845 ,  G01N33/57484 ,  C07K2317/24 ,  C07K2317/31 ,  G01N2333/521

Abstract: This application discloses a CXCL16 antibody for cancer treatment. In some embodiments, a CXCL16 antibody disclosed herein can inhibit the growth of cancer, for example, thyroid cancer, breast cancer, and prostate cancer. Also described is a combination of a CXCL16 antibody with a targeted anticancer agent and/or an immune checkpoint inhibitor for cancer treatment.

公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC classification number: C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12091486B2

公开(公告)日：2024-09-17

申请号：US17810591

申请日：2022-07-01

Applicant: The Board of Regents of The University of Texas System

Inventor： Jinming Gao ,  David Boothman ,  Kejin Zhou ,  Xiaonan Huang ,  Yiguang Wang

IPC: C08F293/00 ,  A61K9/107 ,  A61K9/127 ,  A61K9/50 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K47/58 ,  A61K47/62 ,  A61K47/68 ,  A61K47/69 ,  A61K49/00 ,  A61P35/00 ,  C07D311/92 ,  C08F299/02 ,  C08G81/02 ,  G01N33/58

CPC classification number: C08F293/005 ,  A61K9/1075 ,  A61K9/1273 ,  A61K9/5031 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K47/58 ,  A61K47/62 ,  A61K47/6811 ,  A61K47/6845 ,  A61K47/6907 ,  A61K49/0032 ,  A61K49/0054 ,  A61K49/0056 ,  A61K49/0082 ,  A61P35/00 ,  C07D311/92 ,  C08F299/024 ,  C08G81/025 ,  G01N33/582 ,  A61K49/005 ,  C08F2438/01

Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises




wherein R′ is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.

公开(公告)号：US12090136B2

公开(公告)日：2024-09-17

申请号：US18528691

申请日：2023-12-04

Applicant: RESURGE THERAPEUTICS, INC.

Inventor： Olof Mikael Trollsas ,  John J. Stankus ,  Shahram Shawn Gholami

IPC: A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/337 ,  A61K45/06 ,  A61P35/00

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

公开(公告)号：US12090134B2

公开(公告)日：2024-09-17

申请号：US17873800

申请日：2022-07-26

Applicant: Zhuhai Beihai Biotech Co., Ltd.

Inventor： Qun Sun

IPC: A61K31/337 ,  A61K9/08 ,  A61K38/38 ,  A61K47/42 ,  A61K47/64

CPC classification number: A61K31/337 ,  A61K9/08 ,  A61K38/385 ,  A61K47/42 ,  A61K47/643

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.